Skip to main content

Table 4 Pertussis-antigen-specific IgG GMC in infants at birth, 2, 5 and 13 months of age

From: A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants

  

Maternal TdaP3-IPV

Maternal TdaP5-IPV

Unvaccinated mothers

TdaP5-IPV:DTaP3-IPV

TdaP3-IPV:none

TdaP5-IPV:none

Antigen

Time point

N

GMC (95% CI)

N

GMC (95% CI)

N

GMC (95% CI)

GMR (95% CI)

GMR (95% CI)

GMR (95% CI)

PT

Birth

57

50.06 (37.55–66.75)a

53

35.84 (26.73–48.05)

  

0.72 (0.48–1.07)

  

2 months

61

16.82 (12.64–22.37)

70

10.7 (8.07–14.18)

27

2.64 (1.77–3.94)

0.64 (0.43–0.94)

6.36 (3.82–10.61)

4.05 (2.45–6.68)

5 months

62

30.72 (26.32–35.84)

65

33.55 (28.89–38.96)

45

43.2 (35.5–52.58)

1.09 (0.88–1.35)

0.71 (0.56–0.9)

0.78 (0.61–0.98)

13 months

61

5.07 (3.95–6.51)

63

6.05 (4.56–8.01)

44

6.56 (4.79–9.00)

1.19 (0.82–1.73)

0.77 (0.51–1.16)

0.92 (0.62–1.38)

5:2 months

60

1.89 (1.33–2.69)

65

3.25 (2.29–4.62)

27

14.1 (8.67–22.93)

1.72 (1.05–2.81)

0.13 (0.07–0.25)

0.23 (0.12–0.43)

FHA

Birth

57

245.79 (190.72–316.76)

53

97.44 (78.44–121.03)

  

0.4 (0.29–0.55)

  

2 months

61

66.37 (51.95–84.79)

70

31.74 (26.05–38.68)

27

5.97 (4.02–8.87)

0.48 (0.35–0.65)

11.12 (7.36–16.79)

5.32 (3.55–7.96)

5 months

62

54.52 (47.75–62.25)

65

50.67 (43.92–58.45)

45

67.31 (55.02–82.34)

0.93 (0.77–1.13)

0.81 (0.65–1.01)

0.75 (0.6–0.94)

13 months

61

14.01 (11.25–17.43)

63

18.07 (13.81–23.64)

44

22.2 (17.15–28.72)

1.29 (0.92–1.81)

0.63 (0.44–0.91)

0.81 (0.57–1.17)

5:2 months

60

0.83 (0.65–1.05)

65

1.67 (1.3–2.15)

27

10.37 (6.31–17.04)

2.02 (1.43–2.84)

0.08 (0.05–0.13)

0.16 (0.1–0.26)

PRN

Birth

56

250.13 (160.52–389.77)

52

230.53 (151.1–351.7)

  

0.92 (0.51–1.68)

  

2 months

62

62.51 (39.17–99.75)

70

83.02 (59.29–116.25)

27

2.63 (1.44–4.82)

1.33 (0.76–2.32)

23.73 (11.46–49.15)

31.52 (15.41–64.46)

5 months

62

65.88 (55.66–77.96)

65

53.32 (42.59–66.76)

44

73.85 (54.41–100.22)

0.81 (0.61–1.08)

0.89 (0.64–1.24)

0.72 (0.52–1)

13 months

60

10.47 (8.18–13.42)

63

7.04 (5.33–9.30)

40

11.24 (8.4–15.04)

0.67 (0.47–0.97)

0.93 (0.62–1.39)

0.63 (0.42–0.93)

5:2 months

61

1.06 (0.64–1.75)

65

0.65 (0.45–0.93)

27

26.54 (11.81–59.62)

0.62 (0.34–1.12)

0.04 (0.02–0.09)

0.02 (0.01–0.05)

FIM

Birth

56

34.09 (22.77 –51.04)

53

282.36 (177.32–449.62)

  

8.28 (4.55–15.09)

  

2 months

61

9.82 (6.71–14.37)

70

85.5 (59.59–122.67)

27

5.2 (2.94––9.21)

8.71 (5.2 –14.58)

1.89 (0.96–3.71)

16.43 (8.47–31.88)

5 months

62

3.64 (2.77–4.79)

65

18.47 (13.58–25.12)

45

2.32 (1.73–3.12)

5.07 (3.38–7.61)

1.57 (1.02–2.41)

7.95 (5.19–12.16)

13 months

61

1.54 (1.26–1.87)

63

1.49 (1.24–1.79)

44

1.21 (0.92–1.60)

0.97 (0.75–1.26)

1.27 (0.93–1.72)

1.23 (0.91–1.67)

5:2 months

60

0.38 (0.3–0.48)

65

0.22 (0.19–0.26)

27

0.49 (0.33–0.71)

0.58 (0.44–0.76)

0.79 (0.55–1.14)

0.46 (0.32–0.66)

  1. Abbreviations: DdaP3-IPV low dose diphtheria, tetanus, acellular pertussis (three pertussis antigens), inactivated poliovirus, TdaP5-IPV low dose diphtheria, tetanus, acellular pertussis (five pertussis antigens), inactivated poliovirus, GMC geometric mean concentration, CI confidence interval, GMR geometric mean ratio, PT pertussis toxin, FHA filamentous haemagglutinin, FIM fimbriae types 2 and 3, PRN pertactin
  2. aThe GMC of anti-PT IgG was lower than the limit of detection for one infant at birth
  3. Blood samples were not collected at birth from infants born to women not receiving a pertussis-containing vaccine in pregnancy as these women and infants were only recruited in the postnatal period; therefore, corresponding cells are empty
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us